• MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitors
• The company maintains active partnerships with growing firms in AI, technology, and mental health
• MINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugs
• The company has demonstrated a clear path to near-term revenues and boasts a strong financial position

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health. MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic. MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry. Technology Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers. iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (“MVP”) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch. Research In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions. Market Outlook MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025. The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025. Management Team Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario. Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry. Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain. Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance. Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario. Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Company receives millions in funding from RB Capital Partners
• Funding provided on growth-friendly terms on an important piece of the financial foundation necessary to actualize company potential
• ISWH well positioned to execute on its bottom-line revenue goals

ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and renewable energy cryptocurrency mining, has received $8 million in funding, which the company will use to develop its cryptocurrency mining and telehealth operations. The funding came from California-based RB Capital Partners Inc. “ISW Holdings has built a model with robust growth potential, and we’re excited that RB Capital has seen around that corner and was willing to provide growth-friendly terms on an important piece of the financial foundation necessary to actualize that potential,” said Alonzo Pierce, ISW Holdings president and chairman. “Given the timing of our agreement in Georgia and recent geopolitical shifts in the global cryptocurrency mining landscape, we are positioned very well at this point, and we look forward to a number of significant developments over coming weeks.” RB Capital Partners provided the funding as a premium-to-market convertible note that can only convert at a premium ($1.50 per share) to the stock’s current price (~$0.41 per share); the agreement stipulates that the conversion can only be made after 12 months. ISWH announced that RB Capital also provided for additional funding — potentially up to $12 million — offered along the same terms and to be used for additional exploration and development investment. “We are excited to be a part of ISWH’s growth trajectory and agree the company is now very well positioned to execute on its bottom-line revenue goals,” stated RB Capital Partners owner Brett Rosen. “The elimination of harmful toxic debt, coupled with the Georgia deal, put ISWH on the road to a Nasdaq uplist.” In addition to the actual funding, conditions of the funding stipulate that any capital acquired through the arrangement will be used for further development, including the infrastructure necessary to strengthen and expand cryptocurrency mining operations at ISWH’s new mining facility in Georgia, including the assembly and outfitting of additional POD5 mining pods. The funds can also be used for value-adding strategic investments, such as technology, resources and personnel capable of maximizing the efficiency of ISWH’s operations. ISW Holdings is a diversified portfolio company comprised of essential business lines that serve consumer product demands. The company’s expertise lies in strategic brand development and early growth facilitation, as well as brand identity through its proprietary procurement process. Together with its partners, ISWH seeks to provide a structure that meets large scalability demands and anticipated marketplace needs. The company meets those needs through a variety of strategic innovative processes. ISW Holdings is creating and managing brands across a spectrum of disruptive industries. It maneuvers its proprietary companies through critical stages of market development, which includes conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
• Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
• Cybin is confident this added focus will better enable the evaluation of patient outcomes

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.” Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform. Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model. These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments. Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states. Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Blackbox will install Ceres EcoLoop systems on its 120-acre property in Fairfield, Michigan
• After extensive study, BlackBox has found that VPD-based climate control is the best way to ensure crop health, maximize yield
• Company is in the process of expanding its Michigan operation

Hero Technologies (OTC: HENC) and its wholly owned subsidiary, BlackBox Systems and Technologies, are utilizing Ceres’s EcoLoop(TM), a high-tech, low-cost solution for growing cannabis. Blackbox will install the EcoLoop systems on its 120-acre property in Fairfield, Michigan (https://ibn.fm/Sgyju). The company anticipates that combining EcoLoop with its proprietary, state-of-the-art aeroponic system will increase its high-yield, high-profit cannabis crops. The move was reported in a recent MMJDaily article, which noted that, in January 2020, “Ceres introduced its EcoLoop climate control greenhouse system, a ground-coupled heat pump system designed to heat, cool and dehumidify Ceres’s sealed greenhouses. In effect, EcoLoop combines conventional above-ground HVAC systems with below-ground heat exchange mats. According to Ceres, EcoLoop can reduce energy consumption by up to 60% by decreasing the amount of energy that above-ground systems pull from the electrical grid or other resources.” “What first attracted us to EcoLoop was the installation,” says Marc Kasabasic of BlackBox Systems, an aeroponic cannabis cultivation system that provides optimal conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased efficiencies. “In Fairfield, we don’t have access to natural gas, so we felt that geothermal was the way to go. Also, the fact that the SunSense controller is VPD-based led us to choose Ceres.” The article observed that VPD-based controllers “optimize a ratio of temperature and humidity rather than managing each factor individually. After years of experimenting with environmental optimization, BlackBox has found that VPD-based climate control is the best way to ensure crop health and help maximize yield.” According to the article, BlackBox is in the process of expanding its Michigan operations. The company plans to break ground on 10 acres in September, with the construction of a 27,000-square-foot facility scheduled for completion next year. The new acreage will support four new greenhouses, with 12 more greenhouses in the planning stages. “We expect to harvest once a week, which is exceptional for a facility of this size,” said Kasabasic. “When we have the twelve additional greenhouses, we plan to harvest one greenhouse per week, then clean the entire area before starting again.” BlackBox will use Ceres’ SunChambers in its greenhouses; the SunChambers are sealed to improve environmental control, minimize use of resources and reduce costs. While Ceres provides turnkey greenhouse solutions, the company can also customize its designs to accommodate growers that have their own cultivation systems, such as BlackBox. The sealed SunChambers with VPD control offer BlackBox the ability to recapture condensate from the dehumidification process and recycle it, cutting down on water consumption, resulting in an estimated condensate flow of only 16 gallons per hour in each greenhouse. HENC is working toward a vertically integrated business model. The company’s strategic business plan includes cannabis genetic engineering, space for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multistate operator. The company is planning expansion in cultivation and dispensary operations into both Colorado, through its wholly owned subsidiary Mile High Green LLC, and Massachusetts, through wholly owned subsidiary MassCannabis LLC. In addition, Hero Technologies owns and operates two hemp websites: HighlyRelaxing.com under Highly Relaxing LLC and VeteranHempCo.com. For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Registered Investment Advisors and retail investors cumulatively account for significant proportion of US equity market assets under management
• SRAX’s Sequire platform bridges gap between corporations and their end investors
• SRAX recently introduced automated email and SMS functions, allowing companies to efficiently communicate with millions of retail investors on their platform
• Listed companies will also be able to search and interact with investment advisor community through Sequire’s proprietary search functions

Investment advisors make up a huge segment of the U.S. investor base; according to a recent survey carried out by RIA Channel, there were 14,955 independent registered investment advisors in the United States with cumulative assets under management of $2.969 trillion (https://ibn.fm/gkVER). Meanwhile, retail investors have increasingly become a dominant force within the U.S. equity market; a study carried out by Morgan Stanley revealed that retail investors accounted for close to 10 percent of daily trading volume on the Russell 3000, the broadest U.S. stocks index, after peaking at 15% in September 2020 as widespread lockdowns and increased savings triggered interest in the markets (https://ibn.fm/ecxI4). SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has sought to bridge the gap between listed corporations and the two investor sub-sets through the introduction of a number of novel features on its platform. As of May 2021, SRAX revealed that its Sequire platform had seen its corporate subscriber base swell to 183 publicly listed companies in addition to boasting a network of over five million influential, forward-thinking investors and shareholders. Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function. Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories (https://ibn.fm/mmDe2), along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform. “These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,” said SRAX Founder and CEO Christopher Miglino (https://ibn.fm/u0ITG). SRAX has simultaneously released new search features, enabling companies to access contact information on registered investment advisors. Banking on the knowledge that close corporate interactions with investment advisors make it more likely that a given investment advisor will recommend a company’s stock to clients, the investment advisor feature on Sequire will seek to assist issuers in developing significant connections and ties with the investment advisor community (https://ibn.fm/0deuy). SRAX’s corporate subscribers will be able to search and filter for specific types of advisors, designed to assist them in efficiently contacting their target audience. Moreover, in addition to assisting issuers in communicating with the advisors, the platform will also enable companies to track their subsequent participation in their listed equity. “Registered Investment Advisors have been the largest investors in our company SRAX and have been a significant part of the growth of our shareholder base. We are now providing the tools that will enable issuers to identify, communicate with and track the progress of specific advisors,” stated Christopher Miglino. For more information, visit the company’s websites at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• WTER’s distribution agreement calls for Giant Food to carry select WTER Alkaline88(R) and A88 Infused(R) offerings
• The distributor will offer WTER beverages in all 164 locations.
• Giant Food serves market of 60 million people with over $5 billion in sales.

In an move illustrative of  its continued commitment to expansion and growth, The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) announced that it has partnered with Giant Food, the largest food retailer in the Mid-Atlantic region. The distribution agreement calls for Giant Food to carry select WTER Alkaline88 and A88 Infused offerings in all locations. “This is our biggest win to date in the Mid-Atlantic region,” said WTER president and CEO Ricky Wright. “Giant Food is the largest retailer in that market of 60 million people with over $5 billion in sales. While many retailers will test one or two product offerings, we are pleased to announce that Giant Food is carrying six products from our Alkaline88 and A88 Infused lines in their 164 locations. “The products include our one-gallon and 1.5-liter bottles, and naturally flavored Watermelon, Raspberry, Blood Orange, and Lemon single serves,” he continued. “This year, we expect these and our other single serves to significantly increase their overall contribution to our top line. We couldn’t have hoped for a better start to our fiscal 2022 expansion into the Mid-Atlantic and Northeast regions than being on the shelves in Giant Food. This is just the beginning of a larger push into the remaining untapped markets in the U.S.” Giant Food, a subsidiary of Ahold Delhaize, serves 164 stores in Maryland, Virginia, Delaware and Washington, DC. The company has been in operation for more than 80 years and has become an integral part of its customers’ lives and the communities it serves. The company’s commitment to providing its customers with the best is a perfect match with WTER’s dedication to offering the finest alkaline water products on the market. WTER’s Alkaline88 is known for its superior hydration with a perfect 8.8pH balance. The brand was developed to deliver what the company calls a Deliciously Smooth(TM) taste that encourages consumers to drink more and fully hydrate. The water’s ingredient deck is simple, easy to understand and free of buffers; it contains only two ingredients: purified water and Pink Himalayan Rock Salt. With the Giant Food announcement, the Alkaline88(R) flagship brand of premium alkaline water is now available in 75,000 stores across all trades in the United States. For more information, visit the company’s website at www.TheAlkalineWaterCo.com and www.a88CBD.com. NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER

• Flora Growth is uniquely positioned to achieve revenue growth, with a balance sheet supported by two successful financings and the recent launch of multiple operating divisions
• The company boasts a robust M&A pipeline featuring strategic targets with near-term revenue growth opportunities and global distribution channels
• Flora Growth is led by an exceptional management team featuring cannabis, CPG, and capital markets experts who have raised more than $3 billion in combined public financings
• The company’s brand portfolio features 280+ products, 70+ medical and cosmetic licenses, and 2,500+ points of distribution across Latin America and the U.S.
• Flora Growth has a healthy balance sheet with minimal debt; the company reported a cash balance of $25.3 million with long-term debt of just $0.7 million as of April 19, 2021
• The company’s all-natural, outdoor cultivation operations allow for production costs below $0.06 per gram – roughly 60% lower than its closest peer

Flora Growth (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive. Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors. Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth. Existing Brand & Product Portfolio Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability. Flora Lab S.A.S Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas. Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products. Flora Beauty Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business. Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets. KASA Wholefoods KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country. Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan. Hemp Textiles & Co. Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment. The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021. Accretive M&A Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins. To date, Flora has announced two major transactions. Koch & Gsell (Acquisition)

• Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million
• Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets
• Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis

Hoshi International (Investment)

• Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities
• Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
• Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth

Cultivation Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram. Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward. Leadership Team Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices. Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard. Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia. Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England. Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• The study indicated enhanced delivery of colchicine using the company’s proprietary DehydraTECH(TM) technology
• Lexaria collaborates with the National Research Council (“NRC”), Canada’s leading research and technology organization
• The company has 20 patents granted and over 50 pending patents in over 40 countries around the world
• The global market for advanced drug delivery systems was valued at $231 billion in 2020 and is expected to grow to $310 billion by 2025

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the tolerability and pharmacokinetic study entitled VIRAL-A20-3 was completed and yielded positive results. The study demonstrated that administration of colchicine using the company’s proprietary DehydraTECH(TM), formulation and processing, resulted in increased delivery, according to a company press release (https://ibn.fm/AXBcz). Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the substance potentially beneficial against this form of cardiac inflammation when it occurs as a side effect of mRNA COVID-19 vaccines. The study was performed using Sprague-Dawley rats, with 20 dosed through oral gavage using DehydraTECH or control colchicine formulations. Performed by an independent, premier animal testing laboratory in the United States, the study evaluated both peak concentration and total drug delivery into the rodent’s bloodstream. As colchicine has a narrow therapeutic index, which means there is a marginal difference between toxic and non-toxic doses, Lexaria hopes that by using DehydraTECH it can improve its bioavailability beyond current levels of approximately 45 percent, which would potentially allow lower dosing requirements. Lexaria’s DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery. The method has been evaluated thoroughly through in vivo, in vitro, and human clinical testing. The company has shown, through animal studies, that DehydraTECH technology elevates the quantity of drugs delivered across the blood-brain barrier by as much as 1,900%. This research has initiated new patent applications and opened the possibilities for improved drug delivery. The company has licensed its proprietary technology to multiple companies for use in different industries, including tobacco and nicotine products, cannabinoid beverages and edibles and more. Lexaria’s intellectual property portfolio consists of 20 patents granted and more than 50 patents pending in over 40 countries worldwide. Lexaria is currently collaborating with the National Research Council (“NRC”), the Canadian government’s leading research and technology organization. The Company has already filed for patent protection for specific nicotine delivery, NSAIDs, vitamins, estrogen, testosterone, terpenes, cannabinoids, PDE5 inhibitors (like Viagra), tobacco, and more. DehydraTECH is designed for formulating and delivering fat-soluble drugs and active ingredients, increasing their effectiveness and improving the way active pharmaceutical ingredients enter the bloodstream. The benefits of a DehydraTECH-enabled drug or consumer product are:

• Delivery is sped up, making the effects felt by the consumer in a matter of minutes
• The bioavailability is increased, making the delivery to the bloodstream much more effective and possibly requiring lower doses
• Animal testing has evidenced that there is a significant increase in the amount of the formulation crossing the blood barrier
• For consumer products, eliminates or reduces the need for sweeteners that are often used to mask the unwanted taste of the substance

This technology has the potential to revolutionize the global market for advanced drug delivery systems by changing the way treatments are administered and increasing overall bioabsorption and bioavailability. The drug delivery market is expected to reach a revenue of $310 billion by 2025 from $231 billion in 2020, marking a CAGR of 6.1% (https://ibn.fm/gGqYu). Right now, one of three areas of focus for Lexaria is on the antiviral drug market, which is anticipated to reach $52.1 billion in 2021 and grow to $66.7 billion by 2025. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Israeli Patent Office grants patent for new-generation, natural, disinfecting composition and method to protect edible matter from decay
• Patent is further validation of SVFD’s technology, an important step in building company’s IP portfolio
• Food waste is a social, humanitarian, economic and environment concern

Save Foods (NASDAQ: SVFD), an agri-food tech company focused on creating solutions to food waste and loss as well as food safety, has been granted its seventh global patent, protecting the company’s innovative ecofriendly product-treatment offerings (https://ibn.fm/XGHjr). The patent was granted by the Israeli Patent Office for SVFD’s new-generation natural disinfecting composition and method to protect edible matter from decay, ultimately extending extend shelf life and reduce waste. “Israel is a world-leader in agricultural technologies and a major exporter of fresh produce,” said Dr. Neta Matis, vice president of R&D for Save Foods Ltd.’s Israel subsidiary. “Israel is a key jurisdiction for us to protect our proprietary technologies, and this patent is further validation of our technology and an important step in building an IP portfolio that ensures food safety reduce waste globally.” The patent is Save Foods’ fourth issued patent in Israel and its seventh global patent. These patents are representative of the success of Save Foods’ dedication to addressing two major global issues: food waste and loss, and food safety. At face value, the implications of food waste are immense, with one recent report noting that “the amount of food waste in America alone is simply mind numbing, weighing in at 133 billion pounds and $161 billion worth of food in 2010. That means 31% of all food produced annually is wasted. As a subcategory, 644 million tons of fruit and vegetables, or 42% of total supply, is wasted annually” (https://ibn.fm/MOtc3). In fact, however, “food waste is a social, humanitarian, economic and environment concern. Understand that waste isn’t just what gets thrown away in a kitchen, grocery store or hotel. It also includes product that never leaves the farm or spoils during distribution. Collect those billions of pounds of waste, and there are enough calories to feed every undernourished person on the planet,” the report noted. “Now think about all the energy that was used, not to mention the trillions of gallons of water, to grow, harvest, package and transport the 133 billion pounds of fruit, vegetables, meat and more that ultimately ended up in the Dumpster. “If the United States, along with the rest of the world, genuinely wants to meet carbon reduction targets by 2030, all involved need to take a close look at food waste, considering it accounts for about 8% of global emissions. According to Project Drawdown, when accounting for deforestation for farmland and annual adoption of plant-rich diets, reducing food waste by 50% to 75% by 2050 would reduce carbon dioxide emissions by up to 95.1 gigatons.” Save Foods offers the first natural product with potential to actually replace the different highly residual (hazardous) chemicals used today while also addressing the challenges of both food waste and food safety. The company’s core applications are ecofriendly, post-harvest treatments for fruits and vegetables. SVFD’s proprietary technologies reduce the need for conventional post-harvest fungicide by at least 50% — even entirely in some cases — can reduce food loss due to spoilage by up to 50%. The company is dedicated to delivering integrated solutions for improved safety, freshness and quality, every step of the way from field to fork. Collaborating closely with its customers, Save Foods develops new solutions that benefit the entire supply chain and improve the safety and quality of life of both workers and the consumers alike. For more information, visit the company’s website at www.SaveFoods.co. NOTE TO INVESTORS: The latest news and updates relating to SVFD are available in the company’s newsroom at https://ibn.fm/SVFD

• Canadian-based clean energy solutions innovator FuelPositive Corp. began trading on the OTCQB Venture Marketplace July 21 to increase its North American presence among investors
• The company will also continue trading on the TSX Venture Exchange in Canada
• FuelPositive’s primary IP strategy is to develop scalable and easily transportable commercial ammonia production units that are non-polluting and able to help the carbon-intense ammonia industry evolve
• The company is also increasing its ability to work with the Canadian government on mutual goals by hiring Sussex Strategy Group to provide government relations services
• The potential applications of FuelPositive’s technology extend beyond the agriculture industry, which provides about 80 percent of the world’s demand for ammonia currently, to potential non-polluting fuel for combustion engines and a solution for grid-storage

Canadian-based growth-stage company FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) has kicked in the boosters on its flight toward commercialization of its clean energy IP with the announcement July 21 that its common shares have begun trading on the OTCQB Venture Marketplace under the symbol NHHHF. “We’ve been in application now for a number of months and have gone through all of the qualifications to graduate to the QB so we’re very excited, really for our U.S.-based investors. We have a lot of retail investors in the U.S. and we expect that this will create a lot easier access to trading our stock,” CEO Ian Clifford said (https://ibn.fm/NzXlf). FuelPositive is dedicated to helping the fight against climate change through the development of green solutions that are accessible to the public and that improve on current technologies. The company is currently developing a patent-pending first-of-its-kind carbon-free ammonia (“NH3”) technology that provides a more efficient alternative to current ammonia production through modular, on-site capabilities. Ammonia production is a multi-billion-dollar industry that primarily supplies agricultural needs, an absolutely necessary food-production commerce chain but also a large source of the world’s greenhouse emissions. But FuelPositive’s solution would not only improve the environmental footprint of industry associated with agriculture, it also has the potential to expand into alternative applications including non-polluting fuel for combustion engines and a solution for grid-storage. “Beyond agriculture, there are numerous applications where our carbon-free NH3 can make a massive difference. For instance, we are exploring using our system to provide clean energy for northern and remote communities – that would be an ideal project for us to work on in partnership with governments,” Clifford stated (https://ibn.fm/tN8AK). FuelPositive’s debut on the OTCQB Venture Marketplace grants it greater visibility and liquidity as its potential for growing its investor audience is realized. “We believe the exciting promise of our carbon-free ammonia (‘NH3’) and its role in significantly reducing greenhouse gases across multiple sectors will resonate with institutional and retail investors within the U.S. investor community, opening up enhanced opportunities for engagement,” Clifford stated in a news release about the development (https://ibn.fm/rZw4d). The Company’s common shares will continue to be traded on the TSX Venture Exchange in Canada with its existing symbol NHHH as part of its efforts to build its North American presence. Clifford’s statement on alternative clean energy applications noted that the company has hired Sussex Strategy Group to provide government relations services in Canada, helping the company build on mutual goals it shares with the government under the Paris Agreement. FuelPositive’s carbon-free ammonia product takes air, water and sustainable electricity and converts it into a non-polluting chemical formulation of nitrogen and hydrogen (“NH3”) that can economically, efficiently and quickly produce, store, transport and use hydrogen, which supports current hydrogen fuel economy efforts. FuelPositive’s IP strategy is to develop scalable and easily transportable non-polluting commercial ammonia production units that will allow their end users to make clean NH3 onsite, “wherever it is needed, when it is needed.” The existing ammonia market has been a commodity-type market with a CAGR of 5 percent but the company states that several recent projections suggest the carbon-free ammonia market can achieve a 50 percent CAGR or more in the next decade. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF